Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...

Bybit, the world's second-largest cryptocurrency exchange by trading volume, announced an exclusive opportunity for USDT ...

Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced it is joining the ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1 ...

And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, today’s program is being recorded. At this time, I’d like to turn the call ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs ...

Sarepta Therapeutics has a one year low of $101.15 and a one year high of $173.25. The firm has a market capitalization of $10.15 billion, a P/E ratio of 85.02 and a beta of 0.75. The business has ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against other best fast growth stocks to buy right now. In the fourth quarter of 2024 ...